You are here:
Home
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood and bone marrow cancers
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]
Discontinued
Reference number:
GID-TA11007
Project information
Project documents
28726-Navitoclax-Ruxolitinib-for-Myelofibrosis-V1.0-FEB2022-NON-CONF.pdf (nihr.ac.uk)
Back to top